Corxel

Corxel is a leading biotechnology company committed to bringing innovative cardiometabolic medicines to underserved patients around the world.

We formed Corxel, known as JiXing in China, in early 2020, borne out of a two-year study of innovation, biotechnology, and access to healthcare in Asia. Today, Corxel is a leading biotechnology company with offices in New Jersey, Shanghai, and Beijing, and committed to bringing innovative science and medicines globally to underserved patients living with cardiometabolic diseases.

Founded
2020
Initial RTW investment
2020
Location
Shanghai, China
Phase
Clinical
Tags

Status

Corxel’s pipeline now includes 7 assets focused on cardiovascular and ophthalmology conditions with high unmet need through partnerships with Cytokinetics, Milestone, LENZ Therapeutics, and Oyster Pharma. RTW further capitalized Corxel by providing a Series B and C funding. 

Next catalyst

By working closely with the Corxel team we look to in-license additional late-clinical stage or commercial stage assets into its growing pipeline and provide further capital for business operation expansion.

Pipeline

Preclinical
Phase 1
Phase 2
Phase 3
Registrational
Commercial

  • JX10: Acute Ischemic Stroke (AIS)

  • JX09: Hypertension

  • Aficamten: oHCM

  • Aficamten: nHCM

  • Etripamil: PSVT

  • Tryvaya®: Dry eye disease

  • LNZ100/101: Presbyopia

  • Pre-clinical
  • Phase 1-3
  • Registrational
  • Commercial

Key team members

Peter Fong, PhD

Peter Fong, PhD

Partner, President
Roderick Wong, MD

Roderick Wong, MD

Managing Partner, Chief Investment Officer
EXPLORE THE NEXT COMPANY
Rocket Pharmaceuticals Inc

Speak to a member of our team